The then compared these to calculated incidences of CVT following influenza, and the background level in the general population. Compared to the current COVID-19 vaccines, this risk is between 8-10 times higher, and compared to the baseline, approximately 100 times higher. The breakdown comparison for reported cases of CVT in COVID-19 patients in comparison to CVT cases in those who received a COVID-19 vaccine is:In this study of over 500,000 COVID-19 patients, CVT occurred in 39 in a million patients. Yet, one key question remained unknown: ‘What is the risk of CVT following a diagnosis of COVID-19?’. Firstly, COVID-19 markedly increases the risk of CVT, adding to the list of blood clotting problems this infection causes.
